SCHEMBL3575875

SCHEMBL3575875

COc1ccc(CCCSC)c(N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
THRB P10828 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
MCL1 Q07820 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ESR1 P03372 1/20 0.41
CYP19A1 P11511 1/20 0.41
ESR2 Q92731 1/20 0.41
CYP3A4 P08684 1/20 0.40
ADRA1A P35348 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21321204 0.90 ALDH1A1 (0.49) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL22897755 0.81 ALDH1A1 (0.47) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL2723478 0.80 ALDH1A1 (0.49) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL5217973 0.78 TAAR1 (0.62) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL3816078 0.78 ALDH1A1 (0.50) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL3584957 0.77 SLC6A4 (0.56) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL3579691 0.76 PTGS2 (0.51) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL3580131 0.76 ALDH1A1 (0.48) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL3579011 0.76 ALDH1A1 (0.52) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL28853249 0.76 ALDH1A1 (0.48) ALDH1A1MEN1MAPTTHRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
US-8614215-B2 Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) MERCK SERONO SA (CH) 2013-12-24 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137308-A1 Quinoxaline Compounds and Use Thereof PFKP, PDXK, PF4 ALDH1A1 577/4885MEN1 927/4885MAPT 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.